Hyderabad-based Natco Pharma Ltd and US-based Bristol-Myers Squibb (BMS) have amicably resolved their patent dispute over entecavir, a pharmaceutical combination for treating Hepatitis B, according to a Business Standard report. Both the companies informed about this development to Intellectual Property Appellate Board (IPAB). However, terms of the settlement have not been disclosed.
The patent which was disputed by Natco Pharma and settled in IPAB is for a pharmaceutical composition effective for once a day oral administration to treat Hepatitis B virus infection in a human adult patient comprising up to one per cent of entecavir (owned by BMS), among other ingredients.
FOR COMPLETE REPORT READ: Bristol-Myers Squibb, Natco Pharma settle patent dispute
The patent which was disputed by Natco Pharma and settled in IPAB is for a pharmaceutical composition effective for once a day oral administration to treat Hepatitis B virus infection in a human adult patient comprising up to one per cent of entecavir (owned by BMS), among other ingredients.
FOR COMPLETE REPORT READ: Bristol-Myers Squibb, Natco Pharma settle patent dispute